J&J's 6% slide on an imperfect quarter is a gift to prospective buyers

J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.
Thursday, 15 October 2026
Independent coverage of global markets, trade and finance
Investing
National Trade News capital-markets note (2026-10-13): J&J's 6% slide on an imperfect quarter is a gift to prospective buyers J&J's pharmaceutical division is humming along, and the MedTech problems should… Primary source: original at CNBC Finance (cnbc.com).
J&J's 6% slide on an imperfect quarter is a gift to prospective buyers

J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.